142 307

Cited 0 times in

Cyclic Pamidronate Infusion in Primary Osteoporotic Women

DC Field Value Language
dc.contributor.author채, 봉남-
dc.contributor.author홍, 은경-
dc.contributor.author이, 성규-
dc.contributor.author정, 윤석-
dc.contributor.author이, 관우-
dc.contributor.author김, 현만-
dc.description.abstractBackground: Bisphosphonates are now well established as successful antiresorptive agents for the preventiona and treatment of osteoporosis. We investigated the effect of cyclic intravenous treatment with an aminobisphosphonate, pamidronate in cases of primary osteoporosis. Methods: Eighteen patients with primary osteoporosis (bone mineral density [BMD] t-score < -2.5) received four courses of pamidronate (30 ㎎ with 500 ㎖ normal saline over 2 hours every 3 months). The serum biochemical parameters and bone turnover markers were measured before each treatment. The bone pain score, medication score, and the side effects were also monitored. BMD and simple spine X-ray were performed before and 1 year after of treatment.

Results: BMD at the lumbar spine(L2-4) significantly increased from 0.798±0.110 g/㎠ to 0.860±0.107 g/㎠ after 1 year of treatment with pamidronate: by +8.3±9.4% of baseline. BMDs at the femoral neck, Ward's triangle and the trochanter also increased, but not significantly. Serum total alkaline phosphatase (p<0.05) and urine deoxypyridinoline/creatinine (p=0.069) decreased with treatment. Other bone turnover markers were unchanged. The bone pain score decreased significantly. None

of the patients experienced a new fracture during treatment. The frequency of the side effects following the first infusion was 61.1% (a transient fever and myalgia with flu-like symptoms in 10 patients and mild phlebitis in 1 patient). However, only

two patients complained of flu-like symptoms after seond infusion, and no patient complained following the third infusion. Conclusion: Cyclic intravenous treatment of pamidronate every three months was effective in increasing BMD and in the decresing

bone turnover rate, and was relatively well tolerated in primary osteoporotic women.
dc.titleCyclic Pamidronate Infusion in Primary Osteoporotic Women-
dc.title.alternative일차성 골다공증 여성 환자에서 주기적인 pamidronate 정주 치료-
dc.subject.keywordPrimary osteoporosis-
dc.subject.keywordBone mineral density-
dc.type.localJournal Papers-
dc.citation.titleJournal of Korean Society of Endocrinology-
dc.identifier.bibliographicCitationJournal of Korean Society of Endocrinology, 16(2):221-230, 2001-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
Files in This Item:
Journal of Korean Society of Endocrinology_16(2)_221-230.pdfDownload


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.